Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today
Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today

We deliver Mobile Wallet Market Research and SWOT Analysis from Alternative Energy to Pharmaceuticals and Healthcare Market Research Reports to Digital Media.

Skip to Main Content »

Search Site
Researchers Currently Online:1072

Perrigo Company (PRGO) - Financial and Strategic SWOT Analysis Review

Perrigo Company (PRGO) - Financial and Strategic SWOT Analysis Review

Double click on above image to view full picture

Zoom Out
Zoom In
Additional Information
Price $125.00
Meta Description Perrigo Company (Perrigo) is one of the leading pharmaceutical companies based in the US. It develops, manufactures and distributes over-the-counter products, generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (A
Publisher GlobalData
Date of Report Dec 3, 2013
Quick Overview
Summary

Perrigo Company (Perrigo) is one of the leading pharmaceutical companies based in the US. It develops, manufactures and distributes over-the-counter products, generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API), infant formulas, and consumer products. The company operates its business through four reportable segments, namely, Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, and API. It also provides consumer products such as cosmetics, toiletries, bar soaps, and detergents. Perrigo operates in China, England, Germany, Mexico, Israel and the US. The company acquired 100% of the shares of PBM Holdings, Inc.

Perrigo Company Key Recent Developments

Feb 01, 2013: Perrigo Reports Revenue Of $883m In Q2 Fiscal 2013
Jan 23, 2013: Perrigo To Invest $192m In Holland Township Facility, Create 400 New Jobs
Jan 22, 2013: Perrigo Launches Brand Version Of Nicorette Mini Nicotine Lozenges
Jan 07, 2013: Perrigo Gains FDA Clearance To Manufacture Three Codex-Compliant Infant Formulas
Nov 07, 2012: Perrigo Reports Revenue Of $769.8m In Q1 Fiscal 2013GDPH4204FSA

This comprehensive SWOT profile of Perrigo Company provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Perrigo Company - Key Facts 5
Perrigo Company - Key Employees 6
Perrigo Company - Key Employee Biographies 7
Perrigo Company - Major Products and Services 8
Perrigo Company - History 10
Perrigo Company - Company Statement 14
Perrigo Company - Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Section 2 – Company Analysis 19
Perrigo Company - Business Description 19
Perrigo Company - SWOT Analysis 21
SWOT Analysis - Overview 21
Perrigo Company - Strengths 21
Strength - Diversified Business Segments 21
Strength - Broad Product Portfolio 21
Strength - Operating Efficiency 21
Perrigo Company - Weaknesses 22
Weakness - Concentration of Revenues 22
Perrigo Company - Opportunities 22
Opportunity - Strategic Acquisitions 22
Opportunity - Product Sales 22
Opportunity - Emerging Markets 22
Opportunity - Rising Healthcare Expenditure in the US 22
Perrigo Company - Threats 23
Threat - Intense Competition 23
Threat - Tightening of FDA’s Regulatory Oversight 23
Threat - Uncertain R&D Outcomes 23
Perrigo Company - Key Competitors 24
Section 3 – Company Financial Ratios 25
Financial Ratios - Capital Market Ratios 25
Financial Ratios - Annual Ratios 25
Performance Chart 27
Financial Performance 27
Financial Ratios - Interim Ratios 28
Financial Ratios - Ratio Charts 29
Section 4 – Company’s Lifesciences Financial Deals and Alliances 30
Perrigo Company, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 30
Perrigo Company, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 31
Perrigo Company, Recent Deals Summary 32
Section 5 – Company’s Recent Developments 33
Perrigo Company, Recent Developments 33
Feb 01, 2013: Perrigo Reports Revenue Of $883m In Q2 Fiscal 2013 33
Jan 23, 2013: Perrigo To Invest $192m In Holland Township Facility, Create 400 New Jobs 34
Jan 22, 2013: Perrigo Launches Brand Version Of Nicorette Mini Nicotine Lozenges 34
Jan 07, 2013: Perrigo Gains FDA Clearance To Manufacture Three Codex-Compliant Infant Formulas 34
Nov 07, 2012: Perrigo Reports Revenue Of $769.8m In Q1 Fiscal 2013 35
Oct 10, 2012: Perrigo Receives FDA Approval To Market Mini Nicotine Lozenges 35
Aug 16, 2012: Perrigo Reports Revenue Of $3.2 Billion In Fiscal 2012 35
Jun 21, 2012: Perrigo Plans To Invest $40m In Israel To Expand R&D And Production Of Pharmaceuticals 35
May 18, 2012: Perrigo Announces FDA Final Approval And Launch Of Store Brand OTC Lansoprazole 15mg Capsules 36
May 18, 2012: Perrigo Announces FDA Final Approval And Launch Of Store Brand OTC Lansoprazole 15mg Capsules 36
Section 6 – Appendix 37
Methodology 37
Ratio Definitions 37
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Perrigo Company, Key Facts 5
Perrigo Company, Key Employees 6
Perrigo Company, Key Employee Biographies 7
Perrigo Company, Major Products and Services 8
Perrigo Company, History 10
Perrigo Company, Subsidiaries 16
Perrigo Company, Key Competitors 24
Perrigo Company, Ratios based on current share price 25
Perrigo Company, Annual Ratios 25
Perrigo Company, Interim Ratios 28
Perrigo Company, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 30
Perrigo Company, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 31
Perrigo Company, Recent Deals Summary 32
Currency Codes 37
Capital Market Ratios 37
Equity Ratios 38
Profitability Ratios 38
Cost Ratios 39
Liquidity Ratios 39
Leverage Ratios 40
Efficiency Ratios 40

List of Figures
Perrigo Company, Performance Chart (2008 - 2012) 27
Perrigo Company, Ratio Charts 29
Perrigo Company, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 30
Perrigo Company, Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013 31




...